Cantor Fitzgerald Downgrades Gossamer Bio Inc. (GOSS) to Neutral

Cantor Fitzgerald analyst Olivia Brayer downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Overweight to Neutral.

The analyst comments: "We are downgrading GOSS from Overweight to Neutral after the recent negative Phase 3 readout (PROSERA) - and an unclear regulatory path forward for seralutinib in PAH. Management still plans to take their dataset to the FDA

They are requesting a Type C meeting that they expect to take place in June. Which means we should have a clearer answer on a path forward by July. As previously announced, enrollment is paused in the Phase 3 SERANATA study (PH-ILD). GOSS does have some compelling data, and the drug clearly shows a solid signal. But it's hard for us to get any level of conviction in whether they have a strong case for a path to commercialization. We are moving to the sidelines until we get more clarity later this year."

For an analyst ratings summary and ratings history on Gossamer Bio Inc. click here. For more ratings news on Gossamer Bio Inc. click here.

Shares of Gossamer Bio Inc. closed at $0.42 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Goldman Sachs Downgrades Oddity Tech Ltd (ODD) to Sell, Chops PT in Half
• JPMorgan Downgrades Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) to Neutral